|
Market Closed -
London S.E.
12:35:09 2026-10-28 EDT
|
5-day change | 1st Jan Change | ||
| 82.50 GBX | 0.00% |
|
0.00% | +2.48% |
| 10-15 | Arecor Therapeutics Obtains Patents in Europe, US, India, for Rapid-acting Insulin | MT |
| 10-15 | Arecor Therapeutics Plc Strengthens Patent Protection For Its Proprietary AT278 Product | CI |
| Market Cap | 37.37M 49.79M 44.63M 41.21M 69.65M 4.74B 70.63M 493M 196M 2.48B 187M 183M 7.85B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 31.81M 42.37M 37.98M 35.07M 59.28M 4.03B 60.11M 420M 167M 2.11B 159M 156M 6.68B | EV / Sales 2026 * |
106x | EV / Sales 2027 * | 181x |
| Free-Float |
55.19% | Yield 2026 * |
-
| Yield 2027 * | - |
London S.E.GBX
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| AREC | Delayed | |
Deutsche Boerse AG
| 6UI | Delayed | |
|
Börse Stuttgart
| 6UI | Delayed |
Last Transcript: Arecor Therapeutics plc
| Current month | +13.79% | ||
| 1 month | -6.78% | ||
| 3 months | +29.92% | ||
| 6 months | +25.00% | ||
| Current year | +2.48% |
| 1 week | 81.25 |  | 85 |
| 1 month | 70 | | 90 |
| Current year | 55.27 | | 95 |
| 1 year | 55.27 | | 95 |
| 3 years | 35.4 | | 199 |
| 5 years | 35.4 | | 449 |
| 10 years | 35.4 | | 472 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sarah Howell
CEO | Chief Executive Officer | 51 | 2021-04-12 |
David J. Ellam
DFI | Director of Finance/CFO | - | 2024-11-17 |
Jan Jezek
CTO | Chief Tech/Sci/R&D Officer | - | 2007-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Sarah Howell
BRD | Director/Board Member | 51 | 2021-04-12 |
Mohammad Fazeli
BRD | Director/Board Member | 61 | 2017-08-31 |
Andrew Richards
CHM | Chairman | 66 | 2021-04-12 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 5/20/26 | Free | Chief Executive Officer | 160,000 | 0.4238% | ||
| 5/20/26 | Free | Executive/Senior Manager | 95,000 | 0.2516% | ||
| 5/20/26 | Free | Chief Financial Officer | 105,000 | 0.2781% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | 0.00% | +15.38% | -56.58% | 49.73M | |
| +0.65% | -3.56% | +33.53% | +60.50% | 63.48B | |
| +1.76% | +2.10% | +12.10% | +81.21% | 54.55B | |
| -0.94% | +0.77% | +8.85% | +100.19% | 53.59B | |
| +2.76% | +4.18% | +28.34% | +55.07% | 44.75B | |
| +2.00% | -2.90% | +18.37% | +119.04% | 41.62B | |
| +1.34% | -3.98% | +225.44% | +914.08% | 39.91B | |
| +0.64% | -3.85% | +11.71% | +45.57% | 32.47B | |
| +29.06% | +48.65% | +106.84% | +92.73% | 26.7B | |
| +3.72% | -7.45% | +24.25% | -2.99% | 23.36B | |
| Average | +4.10% | -0.38% | +48.48% | +140.88% | 38.05B | |
| Weighted average by Cap. | +3.23% | -0.29% | +47.55% | +161.44% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 300K 400K 358K 331K 559K 38.04M 567K 3.96M 1.58M 19.91M 1.5M 1.47M 63.05M | 205K 273K 245K 226K 382K 26M 387K 2.7M 1.08M 13.6M 1.02M 1M 43.08M |
| Net income | - | - |
| Net Debt | -5.57M -7.42M -6.65M -6.14M -10.38M -706M -10.52M -73.44M -29.26M -369M -27.79M -27.24M -1.17B | -249K -331K -297K -274K -464K -31.55M -470K -3.28M -1.31M -16.51M -1.24M -1.22M -52.29M |
Employees
33
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-28 | GBX 82.50 | 0.00% | 22,423 |
| 26-10-27 | GBX 82.50 | 0.00% | 54 |
| 26-10-26 | GBX 82.50 | 0.00% | 0 |
| 26-10-23 | GBX 82.50 | 0.00% | 1,466 |
| 26-10-22 | GBX 82.50 | 0.00% | 1,810 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.8250GBP
Average target price
2.505GBP
Spread / Average Target
+203.64%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- AREC Stock
Select your edition
All financial news and data tailored to specific country editions
